Medifast stock holds near 52-week low as revenue outlook weakens

Published on 09/20/2026 at 11:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medifast stock closed at USD 11.79 on September 18, 2026 on the NYSE, far below its recent 52-week high of USD 14.66. Consensus now points to a 27.3 percent revenue decline for the current fiscal year compared with last year.

MED, US58470S1024, Illustration mit AI erstellt.

Medifast Inc. stock (ISIN US58470S1024) closed at USD 11.79 on the New York Stock Exchange on September 18, 2026, leaving the diet and wellness provider valued at about USD 131.6 million and trading close to its 52-week low.

Revenue expectations turn clearly lower

According to ad-hoc-news.de on September 19, 2026, analyst consensus compiled by Zacks now anticipates Medifast’s revenue in the current fiscal year to fall by 27.3 percent compared with the prior year.

This expected drop in sales marks a sharp reversal from historical growth phases and is a key reason why Medifast stock is trading significantly below earlier valuation levels, with the recent market capitalization at around USD 131.6 million as of September 19, 2026.

Stock trades near the bottom of its yearly range

Per an overview from MarketBeat updated on September 19, 2026, Medifast shares ended regular trading at USD 11.79 on September 18, 2026, down 1.40% from the previous session’s close.

The same MarketBeat data show a 52-week range between USD 9.22 and USD 14.66, meaning the September 18, 2026 closing price stands only USD 2.57 above the 52-week low and USD 2.87 below the 52-week high, underscoring the compressed valuation bandwidth that investors currently assign to Medifast stock.

Valuation and trading metrics for investors

According to the valuation snapshot on MarketBeat as of September 19, 2026, Medifast trades at a price-to-book ratio of about 0.65, highlighting that the stock is priced at a substantial discount to its reported book value.

MarketBeat also cites a consensus price target of USD 12.00 for Medifast shares as of September 19, 2026, which implies only a modest upside of roughly 1.8% from the September 18, 2026 closing price of USD 11.79 and suggests that analysts currently see limited near-term recovery potential.

Stock level and market context

The profile data for Medifast on MarketBeat classify the company under personal care products within the broader health and wellness space, while the listing information on ad-hoc-news.de notes that the shares belong to the S&P 600 SmallCap index.

On the secondary-market side, Medifast is also quoted on German exchanges such as Frankfurt and Munich, where recent prices around EUR 10.28 to EUR 10.42 as of September 19, 2026, reported by Reuters, reflect similar valuation levels when translated into USD.

Price as of the latest completed trading day

Medifast stock closed at USD 11.79 on the NYSE on September 18, 2026, with a daily loss of 1.40% compared with the prior session, placing the shares close to the lower end of their 52-week trading corridor and keeping the company’s market capitalization around USD 131.6 million in USD terms.